| CPC G01N 33/6863 (2013.01) [C12Q 1/6883 (2013.01); G01N 33/50 (2013.01); G01N 33/6866 (2013.01); G01N 33/6869 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/525 (2013.01); G01N 2333/5406 (2013.01); G01N 2333/5412 (2013.01); G01N 2333/5421 (2013.01); G01N 2333/5428 (2013.01); G01N 2333/5434 (2013.01); G01N 2333/545 (2013.01); G01N 2333/56 (2013.01); G01N 2333/57 (2013.01); G01N 2560/00 (2013.01); G01N 2570/00 (2013.01); G01N 2800/085 (2013.01); G01N 2800/50 (2013.01); G01N 2800/60 (2013.01)] | 8 Claims |
|
1. A method for identifying organ dysfunction, comprising:
measuring an amount of one or more biomarkers from a biological sample obtained from an organ undergoing machine perfusion, wherein the one or more biomarkers comprise ribulose, ribose, glycolate, oxidized homo-glutathione (GSSG), and ethanolamine;
comparing the amount of the ribulose, ribose, glycolate, oxidized homo-glutathione (GSSG), and ethanolamine to the amount of ribulose, ribose, glycolate, oxidized homo-glutathione (GSSG), and ethanolamine in a control sample or reference value;
determining that the amount of ribose, ribulose, and glycolate is decreased compared to the control sample or reference value and the amount of GSSG and ethanolamine is increased compared to the control sample or reference value and is an indicator of organ dysfunction;
utilizing the amount of ribulose, ribose, glycolate, GSSG, and ethanolamine to select the organ undergoing machine perfusion when the amount of ribose, ribulose, glycolate, GSSG and ethanolamine is a predictor of organ function; and
transplanting the selected organ into a transplant recipient.
|